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Summary
Objective: Although many studies have attempted to describe treatment outcomes in 
patients with drug- resistant epilepsy, results are often limited by the adoption of non-
homogeneous criteria and different definitions of seizure freedom. We sought to 
evaluate treatment outcomes with a newly administered antiepileptic drug (AED) in 
a large population of adults with drug- resistant focal epilepsy according to the 
International League Against Epilepsy (ILAE) outcome criteria.
Methods: This is a multicenter, observational, prospective study of 1053 patients 
with focal epilepsy diagnosed as drug- resistant by the investigators. Patients were 
assessed at baseline and 6, 12, and 18 months, for up to a maximum of 34 months 
after introducing another AED into their treatment regimen. Drug resistance status 
and treatment outcomes were rated according to ILAE criteria by the investigators 
and by at least two independent members of an external expert panel (EP).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
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1 |  INTRODUCTION
Over the past 35 years, several authors have focused on treat-
ment outcomes in epilepsy. Early studies,1,2 followed by 
more recent ones,3–7 attempted to associate the probability of 
becoming seizure- free with the number of antiepileptic drugs 
(AEDs) that previously failed for the patient. However, many 
of these studies have methodological limitations, such as a 
short follow- up period, retrospective design, the use of differ-
ent definitions/criteria for drug- resistant epilepsy, and most 
importantly, different definitions of seizure freedom.8–10 It is, 
therefore, important to adopt homogenous criteria to estab-
lish whether a specific AED was successful or ineffective.
In 2010, an ad hoc task force of the International League 
Against Epilepsy (ILAE) proposed a new definition of 
drug- resistant epilepsy.11 The novelty of this definition is 
the two hierarchical levels for AED response, with Level 
1 categorizing outcomes of each therapeutic intervention 
and Level 2 providing a core definition of drug- resistant 
epilepsy based on how many informative AED trials re-
sulted in treatment failure. The new definition also high-
lights the “pseudo drug resistance” phenomenon, where 
patients are erroneously labeled as drug- resistant.8,12 The 
ILAE document also includes a formal definition of sei-
zure freedom that requires a seizure- free period of either 
12 months or three times the longest interseizure interval 
experienced prior to starting the intervention, whichever 
is longer. Based on this background, the present study was 
designed with the aim of investigating clinical response 
to a newly introduced AED in adults with drug- resistant 
focal epilepsy, as defined by the new ILAE criteria, with 
clinical response for each individual patient categorized 
independently by the investigator (treating physician) and 
by an external expert panel (EP).
2 |  MATERIALS AND METHODS
2.1 | Study design, protocol approvals, 
registrations, and patient consent
This is a multicenter, observational, prospective study of adults 
with drug- resistant focal epilepsy recruited at 43 epilepsy cent-
ers in Italy between 2011 and 2015 (Prometeo Study SP0992). 
The study was approved by ethics committees at all participat-
ing sites, and written informed consent was obtained from all 
participants (or guardians of participants). The study was regis-
tered in the Italian Medicines Agency (AIFA) public register for 
observational studies, and the identifier number was SP0992. A 
copy of the protocol can be requested from the AIFA register 
for observational studies at info_rso@aifa.gov.it.
2.2 | Study population
Patients were enrolled consecutively according to the fol-
lowing inclusion criteria: (1) age ≥ 18 years; (2) established 
diagnosis of epilepsy with focal seizures with or without 
Results: A seizure- free outcome after a newly administered AED according to ILAE 
criteria ranged from 11.8% after two failed drugs to 2.6% for more than six failures. 
Significantly fewer patients were rated by the EP as having a “treatment failure” as 
compared to the judgment of the investigator (46.7% vs 62.9%, P < 0.001), because 
many more patients were rated as “undetermined outcome” (45.6% vs 27.7%, P < 0.001); 
19.3% of the recruited patients were not considered drug- resistant by the EP.
Significance: This study validates the use of ILAE treatment outcome criteria in a 
real- life setting, providing validated estimates of seizure freedom in patients with 
drug- resistant focal epilepsy in relation to the number of previously failed AEDs. 
Fewer than one in 10 patients achieved seizure freedom on a newly introduced AED 
over the study period. Pseudo drug resistance could be identified in one of five cases.
K E Y W O R D S
antiepileptic drugs, drug-resistant epilepsy, epilepsy, outcome, treatment
Key Points
• This study supports the validity of the ILAE treatment 
outcome criteria in clinical practice
• This study provides validated estimates of seizure free-
dom in patients with drug-resistant focal epilepsy in re-
lation to the number of previously failed AEDs
• Fewer than one in 10 patients with drug-resistant focal 
epilepsy achieve seizure freedom on a newly introduced 
AED
• One of five patients presents pseudo drug-resistant 
focal epilepsy 
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bilateral tonic– clonic seizures; (3) uncontrolled seizures 
on current AED treatment, meeting ILAE criteria for drug- 
resistant epilepsy11; (4) clinical need to modify existing 
treatment by introducing another AED, either as an add- on 
or in substitution, and in a combination not previously used; 
(5) longest interseizure interval not exceeding 6 months in 
the 12 months preceding enrollment; (6) ability to reliably 
complete a seizure diary and to adhere to the protocol; and 
(7) willingness to provide written informed consent. Patients 
were excluded if they (1) were scheduled for epilepsy surgery 
or vagus nerve stimulation, (2) had primary generalized sei-
zures, (3) had a history of psychogenic nonepileptic seizures 
or any other potential seizure mimics, (4) had a severe medi-
cal illnesses or short life expectancy, or (5) were participating 
in clinical trials.
Patients were followed prospectively and assessed at time 
0 (baseline, just before introduction of another AED) and at 
6, 12, and 18 months, or more frequently if clinically indi-
cated. An additional visit was scheduled for patients who had 
been seizure- free for at least 2 months (60 days) at the 18- 
month visit, but who had not yet met ILAE criteria for seizure 
freedom. In these patients, the additional visit could be per-
formed up to 16 months after the 18- month visit, to provide 
sufficient time to establish whether seizure freedom had been 
achieved. Therefore, the maximum period of observation be-
tween time 0 and the last visit was 34 months (148 weeks). 
All medications were used according to standard practice, as 
considered appropriate by the treating physician. Adjustments 
in dosage of the newly introduced AED and of concomitant 
drugs were allowed at any time during the study at the discre-
tion of the physician. The study was conducted according to 
Good Clinical Practice guidelines. All data were recorded in 
electronic case report forms (eCRFs). Recorded information 
included demographic and disease- related characteristics, 
and treatment details (dose schedules, titration rates, serum 
drug concentrations, and clinical response) for each AED and 
for other drugs used by the patient in the past and during the 
duration of the trial.
2.3 | Study outcome
The primary end point of the study was clinical response 
to the newly introduced AED. The response status was 
categorized by the investigator as seizure freedom, treat-
ment failure, or undetermined according to ILAE crite-
ria.11 Specifically, seizure freedom refers to absence of 
seizures for a period of at least 12 months or three times 
the longest preintervention interseizure interval, whichever 
is longer; treatment failure refers to occurrence of any sei-
zure during the observation period, provided that the intro-
duced AED had been used appropriately and adequately. 
“Undetermined” refers to outcomes that did not fit with any 
of the previously mentioned categories.
At the end of the follow- up period, all patient data en-
tered in the eCRFs were reviewed independently by two 
members of an ad hoc EP (Table S1) to (1) confirm or 
refute the patient's drug- resistant status at enrollment, (2) 
confirm whether the use of the newly introduced AED was 
appropriate and adequate, and (3) confirm or refute the cat-
egorization of treatment outcome given by the investigator. 
EP members were selected according to their curricula vitae 
and documented expertise in epilepsy. Each individual pa-
tient's eCRFs were assigned to two members of the EP by 
an automated computerized system in a randomized and 
blinded manner, while ensuring that reviewers did not re-
ceive eCRFs for patients enrolled at their own institution. In 
case of disagreement, the two reviewers were unblinded and 
were asked to communicate to resolve the disagreement. If 
the disagreement was not resolved, the EP chair evaluated 
the reviewers’ positions and made the final decision on the 
patient's response category.
2.4 | Statistical analysis
According to the protocol, the primary analysis was conducted 
on the intention- to- treat (ITT) population, which included all 
patients considered to be drug- resistant by the enrolling phy-
sician and who had at least one subsequent clinical evalua-
tion after baseline using the outcome category determined by 
the enrolling physician. A secondary analysis was done on 
the per- protocol (PP) population, which included all patients 
confirmed as drug- resistant by the EP and who had at least 
one subsequent clinical evaluation after baseline using the 
EP- validated outcome category. Frequency of outcome cat-
egories according to investigators and the EP were compared 
using the chi- square test.
3 |  RESULTS
Of 1076 screened patients, 1063 were enrolled in the study 
and 1053 had at least one clinical assessment after baseline 
(ITT population). Of the 1053 patients, 203 (19.3%) were not 
considered drug- resistant by the EP and were instead con-
sidered to have “undetermined” treatment outcomes due to 
various reasons, including suboptimal use of previously tried 
AEDs or lack of adequate information. A resulting total of 
850 patients were thus confirmed to be drug- resistant by the 
EP and had at least one postbaseline assessment (PP popula-
tion; Figure 1). The ITT and PP populations were comparable 
in terms of clinical and demographic characteristics (Table 
1).
Overall, the agreement between EP members was 96.3%, 
and the agreement between investigators and the EP was 
70.4%. A detailed analysis, including reasons for disagree-
ment, is reported in a separate publication.13
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As shown in Table 1, three of four patients in the ITT 
population had already discontinued at least two AEDs in 
the past, with the three most frequent reasons being lack of 
efficacy in 71.8% of cases, lack of efficacy and tolerability 
in 10.6%, and adverse effects in 9.8%. Three- quarters of pa-
tients (74.5%) were taking two or more AEDs at enrollment. 
The frequency distribution of AEDs prescribed in the past, 
continued at enrollment, and introduced at enrollment in the 
ITT population is shown in Figure 2. The three AEDs that 
were most frequently included in the treatment regimen at 
the time of enrollment were carbamazepine (37.6%), leveti-
racetam (LEV; 27.7%), and phenobarbital (26.0%), whereas 
the AEDs most frequently introduced at enrollment were 
lacosamide (LCM; 41.4%), LEV (12.8%), and zonisamide 
(12.1%; Table 2).
A total of 17% of patients from the ITT population with-
drew prematurely from the study as compared with 15.8% 
withdrawals from the PP population (Figure 1). In both pop-
ulations, the most common reasons for withdrawal were lack 
of cooperation, withdrawal of consent, and loss to follow- up. 
Fifteen patients (1.4%) died during the study.
The response to the newly introduced AED, categorized 
according to ILAE criteria, is shown in Table 3. In the ITT 
population, 92 patients (8.7%) were considered by the inves-
tigators to have achieved seizure- free status, and 646 (61.3%) 
were considered treatment failures. Overall, seizure- free 
F I G U R E  1  Disposition of subjects. EP, expert panel; ITT, intention- to- treat; PP, per- protocol
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status was achieved by 17.4% of patients for whom only two 
AEDs had previously failed, with the proportion of patients 
becoming seizure- free decreasing progressively with increas-
ing number of previously failed AEDs (Figure 3A). Less 
than 2% of patients for whom more than six AEDs had failed 
achieved seizure- free status.
The proportion of patients achieving seizure freedom in 
the PP population was 7.6% based on the EP evaluation as 
compared with 8.3% based on the investigators’ judgment 
(Table 3). In line with the disparity in assessments made at 
enrollment, the proportion of patients considered to have 
treatment failures was significantly higher in the investi-
gators’ assessments than in the EP assessments (62.9% vs 
46.7%, χ2 = 53.5, P < 0.0001). Conversely, compared with 
the investigators’ assessment, significantly more patients 
were rated by the EP as having an undetermined outcome 
(Table 3). Overall, seizure- free status as related to the number 
of previously failed AEDs was lower in the PP population 
than in the ITT population (Figure 3B and 3C). Specifically, 
the proportion of patients achieving seizure- free status based 
on EP assessment was 11.8%, 8%, and 4.6% among patients 
for whom two, three, and four AEDs had failed, respectively, 
and <3% for patients for whom more than four AEDs had 
failed.
4 |  DISCUSSION
This is the first study that, in addition to investigating outcome 
of treatment changes according to ILAE criteria,1 provides 
T A B L E  1  Clinical and demographic 
data of the ITT and PP populations
ITT, n = 1053 PP, n = 850
Gender, male, n (%) 504 (47.9%) 419 (49.3%)
Age, y, median (range) 43.4 (18.2- 92.3) 42.9 (18.2- 92.3)
Etiology, n (%)a
Unknown 485 (46.1%) 380 (44.7%)
Structural 533 (50.6%) 440 (51.7%)
Genetic 57 (5.4%) 49 (5.7%)
Other; ie, metabolic, infectious, immune 5 (0.5%) 5 (0.6%)
Age at onset, y, median (range) 13 (0- 86) 12 (0- 86)
Duration of epilepsy, y, median (range) 22 (0- 68) 22 (0- 68)
Intellectual disability, n (%) 234 (22.2%) 195 (22.9%)
History of febrile seizures, n (%) 172 (16.3%) 144 (16.9%)
History of status epilepticus, n (%) 92 (8.7%) 80 (9.4%)
Seizures at baseline per 28 days, median (range)
Focal aware seizures 4 (0.1- 180) 5 (0.2- 180)
Focal impaired awareness seizures 4.0 (0.1- 180) 1.5 (0.2- 180)
Focal to bilateral tonic– clonic seizures 1.0 (0.1- 45) 1.6 1.5 (0.2- 45)
AEDs taken at baseline, n (%)
 Monotherapy 269 (25.6%) 182 (21.4%)
 Dual therapy 512 (48.6%) 424 (49.9%)
 3 AEDs 214 (20.3%) 189 (22.2%)
 >3 AEDs 58 (5.5%) 55 (6.5%)
Previously discontinued AEDs, n (%)
 0 62 (5.9%) —
 1 192 (18.2%) 166 (19.5%)
 2 230 (21.8%) 180 (21.2%)
 3 147 (14.0%) 129 (15.2%)
 4 121 (11.5%) 107 (12.6%)
 5 88 (8.3%) 75 (8.8%)
 6 61 (5.8%) 57 (6.7%)
 >6 152 (14.4%) 136 (16%)
AED, antiepileptic drug; ITT, intention- to- treat; PP, per- protocol.
aSome patients are counted in more than one group. 
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data validated by an independent EP. Agreement between 
expert pairs in applying ILAE criteria for categorization of 
treatment outcome was generally high, as reported in an ear-
lier pilot study by other investigators. Agreement between 
investigators and the EP was very similar to that reported by 
a recent cross- sectional study that validated the ILAE defini-
tion in terms of reliability and validity.14 Interestingly, the 
latter study also concluded that, for both reliability and valid-
ity, the ILAE definition compares favorably with previously 
proposed definitions of drug- resistant epilepsy.
Although in four of five cases the EP confirmed the diag-
nosis of drug- resistant epilepsy made by the investigator at 
enrollment, in one of five patients this diagnosis was not con-
firmed. These findings are in line with results from previous 
studies emphasizing the concept of “pseudo drug resistance,” 
meaning that a sizeable proportion of patients with uncon-
trolled seizures cannot be considered drug- resistant.15,16 
Inclusion of patients with pseudo drug resistance can also 
potentially explain discrepancies across studies in reported 
outcomes of treatment changes in patients considered to be 
drug- resistant.
Some authors have suggested that the ILAE definition 
of drug resistance may be overrestrictive,17–19 and that sei-
zure freedom rates after treatment changes in patients for 
whom two or more AEDs had failed can be substantial, 
from about 20% to >50%.3,5,18–20 However, those studies 
used different definitions of drug resistance, and treatment 
failures in the same studies may be different from the one 
resulting from a correct application of ILAE criteria. In our 
study, as many as 17.4% of patients who had been consid-
ered by the investigator as having experience failure with 
two AEDs achieved seizure freedom, but that proportion 
dropped to 11.8% when outcomes were reassessed by the 
EP and after excluding those cases where the diagnosis of 
drug- resistant epilepsy was not confirmed. Overall, our 
results may be regarded as supporting the validity of the 
ILAE definition of drug resistance and give clear figures on 
the probability of achieving seizure freedom with a newly 
introduced AED in adult patients who have been classified 
as having drug- resistant focal epilepsy, namely one in 10 
after two AED failures and <3% after six or more failures. 
Our findings are in keeping with those reported by other 
authors, with the additional strength of being based on a 
large, externally validated population, evaluated prospec-
tively and according to ILAE criteria. Interestingly, based 
on EP assessment, 45.6% of treatment outcomes were rated 
as undetermined at the end of follow- up. This was mainly 
attributed to failure to attain what the EP considered an ad-
equate AED dose in the presence of persisting seizures, or 
to the decision to discontinue the drug before its potential 
F I G U R E  2  Frequency and distribution of antiepileptic drugs (AEDs) in the intention- to- treat population. BARB, barbexaclone; CBZ, 
carbamazepine; CLB, clobazam; ETX, ethosuximide; FBM, felbamate; GBP, gabapentin; Inclusion, AEDs newly introduced at enrollment; 
LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine; Ongoing, AEDs present in the treatment regime at the time of enrollment; OTH, other 
(eg, clonazepam); OXC, oxcarbazepine; PAST, AEDs used in the past; PB, phenobarbital; PGB, pregabalin; PHT, phenytoin; PHTA, phenytoin 
association; PRM, primidone; RUF, rufinamide; SUL, sulthiame; TGB, tiagabine; TPM, topiramate; VGB, vigabatrin; VPA, valproate; ZNS, 
zonisamide
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could be fully assessed. Therefore, we cannot exclude that 
some of these patients could have achieved seizure freedom 
at a higher dose, which would lead to our study underes-
timating the probability of achieving seizure freedom on 
a newly introduced AED. Although this limitation is ac-
knowledged, in our observational setting a follow- up period 
of up to 34 months was not long enough to achieve seizure- 
free status in these patients.
The definition of seizure freedom is another element 
of novelty of our study. According to the ILAE definition, 
the effectiveness of a pharmacological intervention is 
based on the longest interseizure interval in the 12 months 
preceding the drug trial. It is, therefore, evident that 
patients with infrequent seizures may need a period of 
>12 months without seizures to confirm that an individ-
ual patient responded to a specific drug trial. This point 
has important practical consequences: (1) it allows cli-
nicians to inform patients in advance about the length of 
time that is needed to determine treatment response, and 
(2) it can guide further studies on the concepts of “re-
lapse” and “sustained seizure freedom” in epilepsy. It is 
becoming clear that some patients with epilepsy present 
with a relapsing- remitting pattern as opposed to others 
having an unremittingly chronic time course. However, 
different authors seem to use different definitions of sei-
zure freedom, and there has been considerable variation 
in the interseizure period required to classify a patient 
as having achieved seizure freedom. That some patients 
with drug- resistant epilepsy may subsequently go into 
remission (Figure 3) indicates that a diagnosis of drug 
resistance does not imply that seizures will persist for 
a lifetime,1,9 but the ILAE definition will help in creat-
ing standardized criteria to identify specific prognostic 
categories.
Although our study has several strengths, it also has lim-
itations. First, inclusion criteria were limited to adults with 
focal epilepsy to ensure a relatively homogeneous popula-
tion, but this also implies that results may not necessarily be 
applicable to children or to patients with other types of epi-
lepsy. Second, as discussed above, the probability of achiev-
ing seizure freedom on the newly introduced AED were 
probably underestimated, because a considerable proportion 
of patients had an undetermined outcome at the end of fol-
low- up. Third, this was an observational study, and the choice 
of the newly introduced AED and dosing schedules were left 
to the clinical judgment of the individual investigator. For all 
these reasons, our study may be considered less informative 
than a randomized controlled trial. However, our study pro-
vides “real- life” outcome data with the advantage of being 
externally validated. Lastly, we recognize that a sizeable pro-
portion of patients (about 40%) were started on LCM, and 
therefore outcomes are to some extent related to this drug. 
T A B L E  2  AED introduced at the time of enrollment (intention- 
to- treat population, n = 1053)
AED n
Carbamazepine 36
Clobazam 34
Clonazepam 3
Ethosuximide 2
Felbamate 1
Gabapentin 1
Lacosamide 436
Lamotrigine 72
Levetiracetam 135
Oxcarbazepine 22
Phenobarbital 10
Phenytoin 14
Pregabalin 17
Primidone 8
Rufinamide 22
Sulthiame 2
Tiagabine 2
Topiramate 57
Valproic acid 51
Vigabatrin 1
Zonisamide 127
AED, antiepileptic drug.
ITT population, 
n = 1053 PP population, n = 850
Investigators’ 
assessment Investigators’ assessment EP assessment
Seizure- free 92 (8.7%) 71 (8.3%) 65 (7.6%)
Treatment failure 646 (61.3%) 535 (62.9%) 397 (46.7%)a
Undetermined 315 (29.9%) 244 (27.7%) 388 (45.6%)a
EP, expert panel; ITT, intention- to- treat; PP, per- protocol.
aχ2 = 53.5, df = 2, P < 0.0001 (investigators’ assessment vs EP assessment in the PP population). 
T A B L E  3  Response to the newly 
introduced antiepileptic drug according to 
International League Against Epilepsy 
criteria in the ITT and PP populations
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This is explained by LCM having been introduced in Italy 
near the time of the study, subsequently introduced AEDs 
(perampanel, eslicarbazepine acetate, and brivaracetam) not 
yet being available at that time. Prescribing the newest option 
for patients for whom many other AEDs had already failed is 
a common occurrence, known as the “latest drug phenome-
non,” which seems to affect retention on treatment rather than 
seizure outcomes.21
In conclusion, this study demonstrates that in adults 
with an externally validated diagnosis of drug- resistant 
F I G U R E  3  Treatment outcome in 
relationship to the number of previously 
failed antiepileptic drugs (AEDs). ITT, 
intention- to- treat; PP, per- protocol
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focal epilepsy, seizure freedom rates achieved with a newly 
introduced AED were about 12% for patients who had 
previously experienced failure with two AEDs, becoming 
progressively less likely as the number of previously failed 
AEDs increased. These results may be regarded as support-
ive of the validity of the ILAE definition of drug resistance, 
provide clear validated figures regarding a patient's chances 
of becoming seizure-free on a new drug trial as a function 
of the number of previously failed AEDs, and underline the 
concept that drug resistance is not synonymous with medi-
cal intractability.
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